Skip to main content
SpringerLink
Log in

Metabolic Consequences of Atypical Antipsychotic Drugs

  • Published:
Psychiatric Quarterly Aims and scope Submit manuscript

Abstract

Atypical antipsychotic drugs have become the treatment of choice for psychotic disorders. However, these medications, though certainly superior in many respects to the more traditional medications, have been shown to have a number of untoward consequences. Understanding of the metabolic consequences of these medications is essential for the psychiatrist. The possible development of diabetes, weight gain, and hypertriglyceridemia in patients taking atypical antipsychotics makes it imperative that the prescribing physician regularly monitor patients on these agents. One possible monitoring scheme is outlined and recommendations for treatment are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Meyer JM: Effects of atypical antipsychotics on weight and serum lipids. Journal of Clinical Psychiatry 62(Suppl 27):27-34, 2001.

    Google Scholar 

  2. Henderson DC: Clinical experience with insulin resistance, diabetic ketoacidosis and type 2 diabetes in patients treated with atypical antipsychotic agents. Journal of Clinical Psychiatry 62(Suppl 27):10-14, 2001.

    Google Scholar 

  3. Haupt DW, Newcomer JW: Hyperglycemia and antipsychotic medications. Journal of Clinical Psychiatry 62(Suppl 27):15-26, 2001.

    Google Scholar 

  4. Liebzeit KA, Markowitz JS, Caley CF: New onset diabetes and atypical antipsychotics. European Neuropsychpharmacology 11:25-32, 2001.

    Google Scholar 

  5. Mir S, Taylor D: Atypical antipsychotics and hyperglycaemia. International Clinical Psychopharmacology 16:63-74, 2001.

    Google Scholar 

  6. Dixon L, Weiden P, Delahanty J, et al: Prevalence and correlates of diabetes in national schizophrenia samples. Schizophrenia Bulletin 26(4):903-912, 2000.

    Google Scholar 

  7. Mukherjee S, Decina P, Bocola V, et al: Diabetes mellitus in schizophrenic patients. Comprehensive Psychiatry 37(1):68-73, 1996.

    Google Scholar 

  8. Kostakoglu AE, Yazici KM, Erbas T, et al: Ketoacidosis as a side-effect of clozapine: A case report. Acta Psychiatrica Scandinavica 93:217-218, 1996.

    Google Scholar 

  9. Popli AP, Konicki PE, Jurjus GH, et al: Clozapine and associated diabetes mellitus. Journal of Clinical Psychiatry 58(3):108-111, 1997.

    Google Scholar 

  10. Hagg S, Joelsson L, Mjorndal T, et al: Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. Journal of Clinical Psychiatry 59:294-299, 1998.

    Google Scholar 

  11. Wirshing DA, Spellberg BJ, Erhart SM, et al: Novel antipsychotics and new onset diabetes. Biological Psychiatry 44:778-783, 1998.

    Google Scholar 

  12. Gatta B, Rigalleau V, Gin H: Diabetic ketoacidosis with olanzapine treatment. Diabetes Care 22(6):1002-1003, 1999.

    Google Scholar 

  13. Ober SK, Hudak R, Rusterholtz A: Hyperglycemia and olanzapine. American Journal of Psychiatry 156(6):970, 1999.

    Google Scholar 

  14. Goldstein LE, Sporn J, Brown S, et al: New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 40(5):438-443, 1999.

    Google Scholar 

  15. Sobel M, Jaggers ED, Franz MA: New-onset diabetes mellitus associated with the initiation of quetiapine treatment. Journal of Clinical Psychiatry 60(8):556-557, 1999.

    Google Scholar 

  16. Wirshing DA, Pierre JM, Eyeler J, et al: Risperidone-associated new-onset diabetes. Biological Psychiatry 50:148-149, 2001.

    Google Scholar 

  17. Croarkin PE, Jacobs KM, Bain BK: Diabetic ketoacidosis associated with risperidone treatment? Psychosomatics 41(4):369-370, 2000.

    Google Scholar 

  18. Sernyak MJ, Leslie DL, Alarcon RD, et al: Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. American Journal of Psychiatry 159:561-566, 2002.

    Google Scholar 

  19. Masand PS: Relative weight gain among antipsychotics. Journal of Clinical Psychiatry 60:706-708, 1999.

    Google Scholar 

  20. Henderson DC, Cagliero E, Gray C, et al: Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. American Journal of Psychiatry 157:975-981, 2000.

    Google Scholar 

  21. Casey D: Prevalence of diabetes during extended clozapine and olanzapine treatment Abstact 224. Presented at the Annual Meeting of ACNP, December 10-14, 2000.

  22. Jin H, Meyer JM, Jeste DV: Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: An analysis of 45 published cases. Annals of Clinical Psychiatry 14:59-64, 2002.

    Google Scholar 

  23. Hayek DV, Huttl V, Reiss J, et al: Hyperglykamie und ketoazidose unter olanzapine. Nervenarzt 70:836-837, 1999.

    Google Scholar 

  24. Meatherall R, Younes J: Fatality from olanzapine-induced hyperglycemia. Journal of Forensic Science 47:893-896, 2002.

    Google Scholar 

  25. Meyer JM: A retrospective comparison of weight, lipid, and glucose changes between risperidone-and olanzapine-treated inpatients: Metabolic outcomes after 1 year. Journal of Clinical Psychiatry 63:425-433, 2002.

    Google Scholar 

  26. Koller E, Schneider B, Bennett K, et al: Clozapine-associated diabetes. American Journal of Medicine 111:716-723, 2001.

    Google Scholar 

  27. Koller EA, Doraiswamy PM: Olanzapine-associated diabetes mellitus. Pharmacotherapy 22:841-852, 2002.

    Google Scholar 

  28. Newcomer JW, Haupt DW, Fucetola R, et al: Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Archives on General Psychiatry 59:337-345, 2002.

    Google Scholar 

  29. Cagliero E, Borba CP, Hayden DL, et al: Clozapine and olanzapine induce insulin resistance in patients with schizophrenic disorders. Diabetes 50(Suppl 2): A91Abstract 362-P, 2001.

    Google Scholar 

  30. Cohn TA, Remington G, Kameh H: Hyperinsulinemia in psychiatric patients treated with olanzapine. Journal of Clinical Psychiatry 63:75-76, 2002.

    Google Scholar 

  31. Yazici KM, Erbas T, Yazici AH: The effect of clozapine on glucose metabolism. Experimental and Clinical Endocrinology and Diabetes 106:475-477, 1998.

    Google Scholar 

  32. Melkersson KI, Hulting A, Brismar KE: Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. Journal of Clinical Psychiatry 60(11):783-791, 1999.

    Google Scholar 

  33. Feldman JM, Quickel KE, Jr, Lebovitz HE. Potentiation of insulin secretion in vitro by serotonin antagonists. Diabetes 21:779-788, 1972.

    Google Scholar 

  34. Wilson JP, Downs RW, Jr, Feldman JM, et al: Beta cell monoamines: Further evidence for their role in modulating insulin secretion. American Journal of Physiology 227:305-312, 1974.

    Google Scholar 

  35. Glick ID, Fryburg D, O'Sullivan RL, Siu C, Simpson G: Ziprasidone's benefits versus olanzapine on weight gain and insulin resistance. Annual Meeting of American Psychiatric Association. May 8, 2001. (Abstract).

  36. Berry S: Annual Meeting of ACNP December 2001 (Abstract).

  37. Sasaki J, Funakoshi M, Arakawa K: Lipids and apolipoproteins in patients treated with major tranquilizers. Clinical Pharmacology and Theraeuties 37:684-687,1985.

    Google Scholar 

  38. Muller-Oerlinghausen B: A short survey on untoward effects of Fluperlapine. Arzneimittelforschung 34:131-134, 1984.

    Google Scholar 

  39. Ghaeli P, Dufresne RL: Serum triglyceride levels in patients treated with clozapine. American Journal of Health System Pharmacy 53:2079-2081, 1996.

    Google Scholar 

  40. Ghaeli P, Dufresne RL: Elevated serum triglycerides on clozapine resolve with risperidone. Pharmacotherapy 15:382-385, 1995.

    Google Scholar 

  41. Sheitman BB, Bird PM, Binz w, et al: Olanzapine-induced elevation of plasma triglyceride levels. American Journal of Psychiatry 156:1471-1472, 1999.

    Google Scholar 

  42. Osser DN, Najarian DM, Dufresne RL: Olanzapine increases weight and serum triglyceride levels. Journal of Clinical Psychiatry 60:767-770, 1999.

    Google Scholar 

  43. Meyer JM: Novel antipsychotics and severe hyperlipidemia. Journal of Clinical Psychopharmacology 21:369-374, 2001.

    Google Scholar 

  44. Gaulin BD, Markowitz JS, Caley CF, et al: Clozapine-associated elevation in serum triglycerides. American Jorunal of Psychiatry 156:1270-1272, 1999.

    Google Scholar 

  45. Stanton JM: Weight gain associated with neuroleptic medication: A review. Schizophrenia Bulletin 21:463-472, 1995.

    Google Scholar 

  46. Wirshing DA, Wirshing WC, Kysar L, et al: Novel antipsychotics: Comparison of weight gain liabilities. Journal of Clinical Psychiatry 60:358-363, 1999.

    Google Scholar 

  47. Allison DB, Mentore JL, Heo M, et al: Antipsychotic-induced weight gain: A comprehensive research synthesis. American Journal of Psychiatry 156:1686-1696, 1999.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, State University of New York Health Science Center at Brooklyn, USA

    Harold E. Lebovitz

Authors
  1. Harold E. Lebovitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Harold E. Lebovitz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lebovitz, H.E. Metabolic Consequences of Atypical Antipsychotic Drugs. Psychiatr Q 74, 277–290 (2003). https://doi.org/10.1023/A:1024170622266

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1024170622266

Search

Navigation